Control of Measles by Vaccination It seems likely that the future control of measles will largely depend upon the development of vaccines capable of producing immunity without reactions. Considerable progress has in fact been achieved along these lines and at present it looks as though suitable vaccines may soon be available.
Qualities ofa Measles Vaccine
The two basic requisites of a measles vaccine are that the vaccine should be safe and effective. It should not give rise to serious sequelk, and,any reactions which it may produce will require to be of a transitory and minor character if it is ever to become popular. Moreover vaccination must be followedcertainly in the majority of casesby life-long immunity. Besides these basic qualities it will be an advantage if immunity can be conferred by a single rather than by repeated injections, and if the vaccine is cheap to produce, has good keeping qualities and can be conveniently given concurrently with other vaccines in routine immunization regimes.
Assessment ofMeasles Vaccines
Most of these qualities can only be assessed by field trials, which have accordingly come to play a prominent part in the development of measles vaccines. In most trials four criteria have been used to assess the degree of vaccination reaction: the degree and frequency of pyrexia, the presence and extent of rash, the degree of constitutional disturbance, and the presence of complications. Protection has been assessed by the presence of measles antibody sometimes supplemented by a comparison of incidence of measles in vaccinated and unvaccinated children.
In considering such assessments three points should be borne in mind:
(1) Unless the vaccinated participants are compared with an adequate control group there may be a tendency to impute to the vaccine malaise and pyrexia which are in fact due to other unrelated causes; this is especially so in tropical countries in which it seems quite common to record appreciable pyrexia, attacks of diarrhoea and other symptoms during the period of observation.
(2) Care should be exercised in drawing conclusions about the severity of vaccination reactions when vaccines are tested in different trials. For example, reports of the early vaccines tested outside the United Kingdom indicated that the high temperatures which frequently followed vaccination were not usually associated with pronounced constitutional disturbance, but this was not our experience when similar vaccines were tested here. Differences in the epidemiological background and observation may, of course, have been responsible for the discrepancy. If the relative merits of vaccines or vaccination methods are to be compared the vaccines must be tested in parallel in the same trial.
(3) Although there is abundant evidence of the immunity produced by measles vaccines, field trials have not been in progress long enough to provide authoritative information about the longterm duration of the immunity. Although it is hoped that immunity would be life-longcertainly with living vaccinesthere can be no assurance of this at the present time.
Vaccination Procedures Four main vaccination procedures are now available: (1) Living attenuated vaccine given alone.
(2) Living vaccine given with y globulin to modify the vaccination reactions. (3) Killed vaccine given alone. (4) Killed vaccine followed by living vaccine.
Living attenuated vaccine: Living vaccines have been extensively tested in several countries. At Beckenham the first batches were produced in 1960, and since then the work of developing an effective measles vaccine free from reactions has followed a simple basic pattern. Virus of the Edmonston strain has been subjected to repeated passage in chick cell cultures or embryos. At various stages in this process a batch of vaccine has been made from the passaged virus and the degree of vaccination reactions and capacity to produce antibody has been tested in man. If the trials showed the reactions to be too severe the virus has been subjected to further passage and the tests in man have been repeated at a later stage. Wherever possible batches of vaccine at different stages of passage have been compared in the same trial to determine whether progress has been made.
The first of the trials was a comparison of three batches of vaccine in 1961 at the Fountain Hospital (Aldous et al. 1961 ). Children were allocated by a random method to receive one of the three batches; a fourth group remained unvaccinated. A comparison of the antibody titres after vaccination showed that all vaccines produced a good antibody response. The response was of a similar order with each vaccine. The reactions to vaccination were also similar with each of these three vaccines. About one-third of the children had negligible or very minor reactions but a substantial proportion had pyrexia and constitutional upset and most of the children developed a rash.
It was clear from these results that despite the good immunological response none of the three batches of vaccine used was suitable for use in England. Similar results were reported from a trial in Nigeria (Collard et al. 1961) . In view of these findings attempts were made to attenuate the strain by serial passage, and two further batches were tested after further passage. Both batches produced reactions which were too marked for routine use; in fact little further attenuation seemed to have been achieved.
During this time Professor Hendrickse, Dr Montefiore and Dr Sherman from Ibadan University undertook a methodical series of controlled trials in an effort to find a suitable vaccine. In one such trial a vaccine (20) which had undergone about 70 extra passages was compared with two of the earlier vaccines and an unvaccinated control group. They found that vaccine 20 produced much less pyrexia than the earlier vaccines and indeed as far as constitutional upset was concerned there was little to distinguish the vaccinated children from the unvaccinated control group. These initial findings were confirmed by Professor Hendrickse and his colleagues in a larger study (Hendrickse et al. 1964) . Studies in England by Dr P Benson and Dr N Butler (1964, personal communication) have confirmed these findings.
Taking all these results into account it looks as though a living vaccine attenuated to a degree similar to that of vaccine 20 developed at Beckenham holds considerable promise as a simple, safe and effective method of immunization. Comparative studies with this and other vaccines are at present being undertaken by the Medical Research Council.
Living vaccine with y globulin: This method has been used successfully in the United States, where it has been recommended for public use for a year, and in England (Benson & Butler 1964, personal communication) . The antibody response was adequate and reactions were very slight. The use of y globulin clearly raises problems of supply and expense and on these grounds is inferior to the highly attenuated vaccines given alone. In fact y globulin and measles vaccine can probably be discounted for routine immunization in future. Inactivated vaccine given alone: Another approach is the use of concentrated, formol-inactivated, alum-precipitated vaccine. Three doses have been shown to produce antibody in about 90% of children but the mean antibody titres appear to be rather lower than those produced by living attenuated vaccines. There is also the disadvantage that the antibody may decline to undetectable levels a year after vaccination.
Protection against measles by inactivated vaccines has been shown by field trial to be of the order of 80-90 %, but preliminary reports suggest that after twelve to eighteen months the protective efficacy declines to around 65% (World Health Organization 1963) . At the present time, therefore, there must be reservations about the use of inactivated vaccines, although it must be borne in mind that the development in future of more concentrated vaccines may produce a longer duration of immunity.
Killed vaccine followed by living vaccine: Live vaccine, even the less attenuated batches, administered after inactivated measles vaccine produces a good antibody response with minimal reactions similar to those of the highly attenuated batches given alone. Comparisons are being made in several countries of killed and living vaccine compared with living vaccine given alone. The killed followed by living regime has disadvantages both on the grounds that several injections are required and also of expense, but there may be advantages in the degree of immunity and freedom from even minor reactions.
